Alzheimers Disease Therapeutics Market to grow by USD 3.99 Bn by 2026, Market Segmentation by Drug Class and Geography - Technavio

NEW YORK, Nov. 14, 2022 /PRNewswire/ -- The Alzheimers disease therapeutics market is projected to grow by USD 3.99 billion, accelerating at a CAGR of  8.76% from 2021 to 2026. 37% of the growth will originate from North America. Technavio categorizes the global Alzheimers's disease therapeutics market as a part of the pharmaceutical market. To leverage the current options, market vendors must strengthen their foothold in the fast-growing segments, while maintaining their positions in the slow-growing segments. Request a Free Sample Report.

Alzheimers Disease Therapeutics Market 2022-2026: Segmentation Analysis

• Drug class
• Cholinesterase Inhibitors
• Significant progress has been made in understanding the basic neurobiology of Alzheimer's disease, leading to the availability of novel medications to treat the illness. One of them is cholinesterase inhibitors.  The main factors contributing to the reduction in cognitive abilities in Alzheimer's disease patients are the degeneration of cholinergic neurons in the brain and the loss of neurotransmission. As a result, one of the potential therapeutic approaches is to raise cholinergic levels in the brain by preventing acetylcholinesterase from performing its essential function. This, in turn, will drive segment growth during the forecast period.
• N-methyl-D-aspartate Receptor Antagonists
• Other Drug Class
• Geography 
• North America
• North America will account for 37% of market growth. The primary markets for AD treatments in North America are the United States and Canada. The market in this region will grow faster than the market in ROW. Increased investment in the development of innovative medicines to treat Alzheimer's disease would aid the growth of the AD therapeutics market in North America over the forecast period.
• Europe
• Asia
• Rest Of World (ROW)

To know additional highlights and key points on various market segments and their
impact in coming years, Download a Free Sample Report.

Alzheimers Disease Therapeutics Market 2022-2026: Vendor Analysis and Scope

The market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• AB Science SA
• AbbVie Inc.
• AgeneBio Inc.
• Aurobindo Pharma Ltd.
• Biogen Inc.
• Denali Therapeutics Inc.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Grifols SA
• H Lundbeck AS
• Johnson and Johnson
• Lupin Ltd.
• Neuronascent Inc.
• Novartis AG
• Shanghai Green Valley Pharmaceuticals Co. Ltd.
• Spinogenix Inc.

Find additional highlights on the growth strategies adopted by vendors and their product
offerings, Buy a Free Sample Report.

The report also covers the following areas:

• Alzheimers Disease Therapeutics Market size
• Alzheimers Disease Therapeutics Market trends
• Alzheimers Disease Therapeutics Market industry analysis

One of the major factors driving the expansion of the AD therapies market is the availability, study, and development of novel biomarkers. Another market trends for AD treatments that are promoting the expansion of the therapeutics market for Alzheimer's disease are the emergence of regenerative therapies. However, factors such as the high cost of therapeutics development may threaten the market's growth.

Alzheimers Disease Therapeutics Market 2022-2026: Key Highlights

• CAGR of the market during the forecast period 
• Detailed information on factors that will assist alzheimers disease therapeutics market growth during the next five years
• Estimation of the alzheimers disease therapeutics market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the alzheimers disease therapeutics market
• Analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of alzheimers disease therapeutics market vendors

Get lifetime access to our Technavio Insights! Subscribe to our "Basic Plan" billed
annually at USD 5000.

Related Reports:
Nootropics Market by Formulation and Geography - Forecast and Analysis 2022-2026: This report extensively covers the nootropics market segmentation by formulation (capsules, powder, drinks, and others) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

Breast Cancer Therapeutics Market by Product and Geography - 2022-2026: The report extensively covers the breast cancer therapeutics market segmentation by product (targeted therapy, hormonal therapy, and chemotherapy) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

Table of Contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Drug Class

• 5.1 Market segments 
• Exhibit 24: Chart on Drug Class - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Drug Class - Market share 2021-2026 (%)

• 5.2 Comparison by Drug Class 
• Exhibit 26: Chart on Comparison by Drug Class
• Exhibit 27: Data Table on Comparison by Drug Class

• 5.3 Cholinesterase inhibitors - Market size and forecast 2021-2026 
• Exhibit 28: Chart on Cholinesterase inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Cholinesterase inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Cholinesterase inhibitors - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Cholinesterase inhibitors - Year-over-year growth 2021-2026 (%)

• 5.4 N-methyl-D-aspartate receptor antagonist - Market size and forecast 2021-2026 
• Exhibit 32: Chart on N-methyl-D-aspartate receptor antagonist - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on N-methyl-D-aspartate receptor antagonist - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on N-methyl-D-aspartate receptor antagonist - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on N-methyl-D-aspartate receptor antagonist - Year-over-year growth 2021-2026 (%)

• 5.5 Other drug class - Market size and forecast 2021-2026
• Exhibit 36: Chart on Other drug class - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Other drug class - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Other drug class - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Other drug class - Year-over-year growth 2021-2026 (%)

• 5.6 Market opportunity by Drug Class 
• Exhibit 40: Market opportunity by Drug Class ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 42: Chart on Market share by geography 2021-2026 (%)
• Exhibit 43: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 44: Chart on Geographic comparison
• Exhibit 45: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026 
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Canada - Market size and forecast 2021-2026
• Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.9 UK - Market size and forecast 2021-2026
• Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.10 Germany - Market size and forecast 2021-2026
• Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.11 Japan - Market size and forecast 2021-2026
• Exhibit 78: Chart on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on Japan - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on Japan - Year-over-year growth 2021-2026 (%)

• 7.12 China - Market size and forecast 2021-2026
• Exhibit 82: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 83: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 84: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 85: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.13 Market opportunity by geography 
• Exhibit 86: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 87: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 88: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 89: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 90: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 91: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 92: Matrix on vendor position and classification

• 10.3 AbbVie Inc. 
• Exhibit 93: AbbVie Inc. - Overview
• Exhibit 94: AbbVie Inc. - Product / Service
• Exhibit 95: AbbVie Inc. - Key offerings

• 10.4 Aurobindo Pharma Ltd. 
• Exhibit 96: Aurobindo Pharma Ltd. - Overview
• Exhibit 97: Aurobindo Pharma Ltd. - Product / Service
• Exhibit 98: Aurobindo Pharma Ltd. - Key offerings

• 10.5 Eisai Co. Ltd. 
• Exhibit 99: Eisai Co. Ltd. - Overview
• Exhibit 100: Eisai Co. Ltd. - Business segments
• Exhibit 101: Eisai Co. Ltd. - Key offerings
• Exhibit 102: Eisai Co. Ltd. - Segment focus

• 10.6 Eli Lilly and Co. 
• Exhibit 103: Eli Lilly and Co. - Overview
• Exhibit 104: Eli Lilly and Co. - Product / Service
• Exhibit 105: Eli Lilly and Co. - Key offerings

• 10.7 H Lundbeck AS 
• Exhibit 106: H Lundbeck AS - Overview
• Exhibit 107: H Lundbeck AS - Product / Service
• Exhibit 108: H Lundbeck AS - Key offerings

• 10.8 Johnson and Johnson 
• Exhibit 109: Johnson and Johnson - Overview
• Exhibit 110: Johnson and Johnson - Business segments
• Exhibit 111: Johnson and Johnson - Key news
• Exhibit 112: Johnson and Johnson - Key offerings
• Exhibit 113: Johnson and Johnson - Segment focus

• 10.9 Lupin Ltd. 
• Exhibit 114: Lupin Ltd. - Overview
• Exhibit 115: Lupin Ltd. - Product / Service
• Exhibit 116: Lupin Ltd. - Key news
• Exhibit 117: Lupin Ltd. - Key offerings

• 10.10 Novartis AG 
• Exhibit 118: Novartis AG - Overview
• Exhibit 119: Novartis AG - Business segments
• Exhibit 120: Novartis AG - Key offerings
• Exhibit 121: Novartis AG - Segment focus

• 10.11 Teva Pharmaceutical Industries Ltd. 
• Exhibit 122: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 123: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 124: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 125: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 126: Teva Pharmaceutical Industries Ltd. - Segment focus

• 10.12 Viatris Inc. 
• Exhibit 127: Viatris Inc. - Overview
• Exhibit 128: Viatris Inc. - Business segments
• Exhibit 129: Viatris Inc. - Key offerings
• Exhibit 130: Viatris Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 131: Inclusions checklist
• Exhibit 132: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 133: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 134: Research methodology
• Exhibit 135: Validation techniques employed for market sizing
• Exhibit 136: Information sources

• 11.5 List of abbreviations 
• Exhibit 137: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio